112 related articles for article (PubMed ID: 2477048)
1. Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
Nowrousian MR; Meier CR; Schoetensack B; Anders C; Höffken K; Osieka R; Schmidt CG
Acta Oncol; 1989; 28(4):495-500. PubMed ID: 2477048
[TBL] [Abstract][Full Text] [Related]
2. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
3. Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
Steinke B; Krüger HU; Kraft H; Heim ME; Günther E; Arnold H; Busch FW
Blut; 1988 Jun; 56(6):269-71. PubMed ID: 2454690
[TBL] [Abstract][Full Text] [Related]
4. Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
Steinke B; Bross K; Reinold HM; Heim ME; Schalk KP; Heidemann E; Josten K; Arnold H; Manegold C; Hoffman I
Eur J Cancer; 1992; 28(1):100-4. PubMed ID: 1373634
[TBL] [Abstract][Full Text] [Related]
5. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
[TBL] [Abstract][Full Text] [Related]
6. [Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
Steinke B; Kraft A; Reinold HM; Heim ME; Löffler B; Heidemann E; Richter C; Josten K; Bross K; Hofmann I
Onkologie; 1989 Feb; 12(1):19-21. PubMed ID: 2469999
[TBL] [Abstract][Full Text] [Related]
7. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
8. [Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
Rev Med Chil; 1991 Sep; 119(9):990-1000. PubMed ID: 1726958
[TBL] [Abstract][Full Text] [Related]
9. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
11. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
12. German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Gerhartz HH; Thiel E; Brittinger G; Dörken B; Engelhard M; Engert W; Enne W; Fuchs R; Hagen-Aukamp CH; Huhn D
Blut; 1988 Mar; 56(3):139-42. PubMed ID: 2451551
[No Abstract] [Full Text] [Related]
13. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
15. Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.
Cabanillas F; Burgess MA; Bodey GP; Freireich EJ
Am J Med; 1983 Mar; 74(3):382-8. PubMed ID: 6187213
[TBL] [Abstract][Full Text] [Related]
16. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
17. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
18. [Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Siegert W; Huhn D; Neubauer A; Brittinger G; Engelhard M; Gerhartz H; Heinz R; Meusers P; Stacher A; Thiel E
Onkologie; 1988 Feb; 11(1):30-4. PubMed ID: 2452392
[TBL] [Abstract][Full Text] [Related]
19. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]